Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
On March19, 2018, the Company held a conference call to discuss the results of its Phase 2 clinical trial of rezafungin, called the STRIVE study. The conference call transcript and slide presentation that was presented on the call are attached hereto as Exhibits 99.1 and 99.2, respectively. The call will be archived and accessible at www.cidara.com for approximately thirty days.
Item 7.01 Financial Statements and Exhibits.
(d) Exhibits
Cidara Therapeutics, Inc. ExhibitEX-99.1 2 ex9912018-03x19_02.htm STRIVE PHASE 2 PART A TOPLINE DATA CONFERENCE CALL TRANSCRIPT Exhibit Exhibit 99.1Cidara Therapeutics,…To view the full exhibit click here
About Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.
